Clinical Trial Update: Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update for Cadonilimab (AK104) with or without chemotherapy as second-line treatment for extensive-stage small cell lung cancer (ES-SCLC) is in pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer Extensive Stage

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Second Affiliated Hospital of Zunyi Medical University | Conditions: Immunotherapy, Second-line Treatment | Phase 2 | Status: UNKNOWN